Understanding the effects of anti-amyloid treatments in Alzheimer's disease
Mechanism of ARIA following Anti-Amyloid Immunotherapy
This study is looking at how certain treatments for Alzheimer's that target harmful proteins in the brain might cause side effects like inflammation and bleeding, and it aims to find ways to make these treatments safer for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11060798 on NIH RePORTER |
What this research studies
This research investigates how monoclonal antibody treatments, designed to remove amyloid-beta from the brains of Alzheimer's patients, can lead to complications such as inflammation and bleeding. The team will study the mechanisms behind these complications, known as Amyloid-Related Imaging Abnormalities (ARIA), by using advanced imaging techniques and mouse models. By identifying the factors that contribute to ARIA, the research aims to develop safer strategies for administering these promising therapies to patients with Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who may be considering or currently receiving anti-amyloid immunotherapy.
Not a fit: Patients with other forms of dementia or those not eligible for anti-amyloid treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Alzheimer's disease, improving patient outcomes.
How similar studies have performed: Previous research has shown that understanding the mechanisms of ARIA can lead to improved treatment protocols, indicating potential for success in this area.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Urayama, Akihiko — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Urayama, Akihiko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.